Tagged with janssen

China Given the undeniably challenging and dynamic China market, most industry stakeholders would agree that the paramount factor behind the success of multinationals’ China affiliates is talent – not only at the top leadership level but throughout the organization. A few country managers share their talent strategies, as well as the…

Taiwan Shuhei Sekiguchi, recently-appointed managing director of Janssen Taiwan, discusses how his vast experience in marketing and sales will help him in this new role, Janssen´s market outlook for Taiwan, its strategy for educating key stakeholders, and the importance of talent acquisition and retention.   Taiwan is conducive to attracting R&D…

Sweden Berkeley Vincent, managing director of Janssen in the Nordics and Baltics, discusses the challenges of the digital future for the Swedish affiliate and the whole healthcare industry and highlights Janssen’s strong involvement in the innovative Swedish R&D ecosystem. He also explains why Sweden is in a unique position to lead…

Europe Janssen’s EMEA market access head Martin Price outlines the regulatory changes that need to be made for patients across Europe to better access cutting-edge cancer medicines.   Recent advances in medical science are the driving force behind the research and successful development of innovative cancer treatments in Europe. By targeting…

Japan Japan’s Opportunity to Establish a Blueprint for the World: Janssen Japan’s Chris Hourigan makes the case for increased investment in, and access to, innovative medicines as a key solution to countering the costs associated with an ageing population.   Earlier this year, Emperor Naruhito ascended the Chrysanthemum Throne, and Japan…

Janssen PharmaBoardroom recently sat down with Janssen EMEA head Kris Sterkens, who outlined the enduring importance of Europe to the global group, even with the emergence of Asian power markets such as China and the continuing significance of the USA. Read the full interview here.   Where Europe really does excel…

Janssen In this exclusive and wide-ranging interview, Janssen’s EMEA head Kris Sterkens outlines the company’s strategies in Europe, its increasing embrace of digital solutions, and the shift toward pre-emptive and precision treatments. Sterkens also highlights how Janssen is positioning itself in the emerging markets under his remit and how the ongoing…

Egypt Ramez Mohsen, managing director at Janssen for Egypt, Jordan, Libya & Sudan, highlights how the company is driving real access to treatments in Egypt through collaboration with various stakeholders. He also assesses Egypt’s attractiveness for clinical trials and the initial results of the government’s prioritization of healthcare.   As the…

China Asgar Rangoonwala, president of Xian Janssen, Janssen’s Chinese affiliate, shares the key milestones for the affiliate in the past two years, how Janssen is investing in bringing new innovations to the Chinese market with a phenomenal 14 new products approved in 2018, and their commitment to working with all stakeholders…

Diversity Annually, PharmaBoardroom conducts hundreds of interviews with global CEO’s, country managers and industry leaders in the pharma industry. While we have crossed paths with many inspiring females in these positions, out of the top 50 pharma companies, only 3 are headed by women. That is a mere 6% — this…

Switzerland Jane Griffiths, global head of Actelion – acquired in 2017 by Johnson & Johnson – discusses her priorities heading up an iconic rare disease-focused biotech and gives her take on a wide range of hot-button industry issues; from the future of M&As to patient-centricity, women in leadership and digital disruption.…

France Emmanuelle Quilès, CEO of Janssen France, speaks about how she joined the American multinational with the ambition to bring digitalization and transform the organization from the inside. Quilès goes on to cover the operational specifics of the affiliate and shares her insights on the French pharma ecosystem.   When I…